Opinion|Videos|July 16, 2024
BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment
Heidi Crayton, MD, discusses the rationale for investigating Bruton tyrosine kinase inhibitors (BTKis) as a treatment for patients with multiple sclerosis and the current stage of development for evobrutinib, tolebrutinib, and other BTKis.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What was the rationale for the investigation of Bruton tyrosine kinase inhibitors (BTKis) for use as treatment in patients with multiple sclerosis (MS)?
- What is the stage in development for evobrutinib, tolebrutinib and other BTKis?
- How might these therapies fit into treatment algorithms for different types of MS?
- How do payers see these therapies being integrated into treatment algorithms?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology
2
5 Questions Dermatology Patients May Have About Newly-Approved Bemotrizinol
3
Venetoclax-Obinutuzumab Tops Acalabrutinib in First-Line CLL
4
Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer
5